Señales en vivo de SANN.SW | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 11:30):

Stats
Volumen de hoy	18 571.00
Volumen promedio	25 397.00
Capitalización de mercado	82.21M
EPS	CHF0 ( 2024-04-24 )
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-1.090
ATR14	CHF0.0660 (0.71%)

Santhera Pharmaceuticals Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Santhera Pharmaceuticals Finanzas

Annual	2023
Ingresos:	CHF103.38M
Beneficio Bruto:	CHF99.51M (96.26 %)
EPS:	CHF4.84

FY	2023
Ingresos:	CHF103.38M
Beneficio Bruto:	CHF99.51M (96.26 %)
EPS:	CHF4.84

FY	2022
Ingresos:	CHF7.47M
Beneficio Bruto:	CHF3.88M (51.93 %)
EPS:	CHF-11.67

FY	2021
Ingresos:	CHF-1.60M
Beneficio Bruto:	CHF-5.36M (-336.18 %)
EPS:	CHF-4.17

Financial Reports:

No articles found.

Santhera Pharmaceuticals

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.